| Document |
Document Title |
|
WO/2020/116555A1 |
The present invention addresses the problem of providing: a liquid crystal composition which contains a polymerizable compound and which is used for producing a PSA type or PSVA type liquid crystal display element, wherein the speed of p...
|
|
WO/2020/107124A1 |
The present invention provides a method of modulating leukocytes activation (e.g., adhesion and/or transmigration and/or cytokine response) and a method of modulating thrombocyte clearance comprising administering to a subject in need th...
|
|
WO/2020/105061A1 |
This invention is related to an improvement in the process of filtrate extension of a reaction where at least a set of filtrates of a set of reaction are mixed together to form for a filtrate extension thereby the reaction yields higher ...
|
|
WO/2020/089134A1 |
The invention relates to a process for preparing 2-substituted 4-methyl-tetrahydropyrans from 2-substituted 4-hydroxy-4-methyl-tetrahydropyrans as starting materials.
|
|
WO/2020/084559A1 |
The present invention is directed to glucopyranose derivatives of formula (I), pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT2 activity. More particularly, the com...
|
|
WO/2020/086691A1 |
This current disclosure is directed to charge-transfer heptamethine dyes for NIR singlet oxygen generation, each such dye comprising a near-infrared (NIR) absorbing dye having heptamethine linkages orthogonally coupled to an optionally s...
|
|
WO/2020/084560A1 |
The present invention is directed to glucopyranose derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT2 activity. More particularly, the compounds of the p...
|
|
WO/2020/079052A1 |
The present invention refers to dihydropyran derivatives, and to a process of making the same. The invention further refers to perfume compositions and fragranced articles comprising them.
|
|
WO/2020/076920A1 |
The present disclosure provides compositions and methods for metathesizing a first alkenyl or alkynyl group with a second alkenyl or alkynyl group, the composition comprising a ruthenium metathesis catalyst and a photoredox catalyst that...
|
|
WO/2020/071550A1 |
The present invention provides a novel CDK8 inhibitor. The present invention relates to: a compound represented by general formula (I) (wherein the symbols are as defined in the description) or a pharmaceutically acceptable salt thereof;...
|
|
WO/2020/067457A1 |
The objective of the present invention is to provide a compound which may be useful for preventing or treating constipation or the like. The present invention provides a compound represented by formula (I) [each symbol in the formula is ...
|
|
WO/2020/068661A1 |
Methods of preparing, and solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-
yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(m
ethylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide,
and salts, s...
|
|
WO/2020/059790A1 |
The the present invention addresses the problem of providing a DP receptor antagonist. Compounds represented by general formula (I): (in the formula, all of the symbols are as defined in the specification) and pharmacologically acceptabl...
|
|
WO/2020/056553A1 |
The invention belongs to the field of organic chemistry, and particularly relates to a method for preparing a heterocyclic compound represented by formula I and salts thereof. Compared with the prior art, the invention avoids the use of ...
|
|
WO/2020/054226A1 |
A thermal base generator is represented by formula (N1). This photosensitive resin composition contains the thermal base generator and a precursor of a heterocycle-containing polymer. In formula (N1), RN1 and RN2 each independently repre...
|
|
WO/2020/050361A1 |
The purpose of the present invention is to provide a method for quickly reducing a C-aryl-hydroxy glycoside derivative that is represented by formula (2) at a low temperature and highly selectively producing a β-C-aryl glycoside derivat...
|
|
WO/2020/039092A2 |
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...
|
|
WO/2020/039094A1 |
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...
|
|
WO/2020/039088A2 |
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...
|
|
WO/2020/035782A1 |
The present invention relates to compounds according to structure (I) whereby one of R1 to R3 is -OCOCD3 and the other two are either hydroxyl or OAc, their synthesis and their use in for the analysis of the metabolism of glycolysis inhi...
|
|
WO/2020/029114A1 |
Disclosed is a production process for preparing high-purity dehydroacetic acid by using melt crystallization, the process including the following steps: first introducing chilled brine into the bottom of a jacket on the outside of a melt...
|
|
WO/2020/023323A1 |
Disclosed herein is a small molecule targeted drug conjugate for anti-influenza chemotherapy and immunotherapy. The disclosed drug conjugate may form an adaptor to recruit additional CAR T cells or other immune cells for precise eliminat...
|
|
WO/2020/023368A1 |
Described are novel derivatives of pogostone of formula (I) and methods of using the same.
|
|
WO/2020/021113A1 |
The invention relates to a process to prepare a compound of the following formula (I): (I), in which P represents a protective group of a hydroxyl function which is a -COR1 group with R1 representing an aryl or a (C1C6)alkyl, R represent...
|
|
WO/2020/015343A1 |
The present invention provides compounds of Formula (I) which can be used as ACC inhibitors and potently as therapeutic agents against diseases mediated by ACC.
|
|
WO/2020/012336A1 |
Disclosed herein are new C-mannoside compounds and compositions and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment di...
|
|
WO/2019/204753A9 |
A method of making of 1,2,5,6-hexanetetrol ("tetrol"). The method includes the steps of contacting a reaction solution containing water as well as levoglucosenone, dihydrolevoglucosenone, and/or levoglucosanol, with a catalyst ontaining ...
|
|
WO/2020/003599A1 |
Provided is a polar compound that has a high chemical stability, a high ability to align liquid crystal molecules, and a high solubility in a liquid crystal composition, and allows a liquid crystal display element to have a high voltage ...
|
|
WO/2019/238121A1 |
Disclosed herein are small molecule compounds having aggregation-induced emission (AIE) characteristics include donor-acceptor (D-A) structural NIR fluorophores based on 1, 3-bis (dicyanomethylene) indan (BDCI), The compounds function as...
|
|
WO/2019/228994A1 |
This invention relates to oleic acid derivative comprising a hydrophobic part C17H33 linked to a particular polar head part "A", especially for use as a medicament, for instance, for the treatment of a disorder caused by the GPR120 recep...
|
|
WO/2019/191352A9 |
Disclosed herein are methods, sodium-dependent glucose transporter (SGLT)1 compounds and compositions for the treatment of postprandial hypoglycemia, postprandial hypoglycemia that occurs as a consequence of gastric surgery.
|
|
WO/2019/226490A1 |
Provided is a compound of Formula (I), wherein the variable groups are defined herein.
|
|
WO/2019/222269A1 |
Provided are biaryl amides and coumarin-based compounds with modified sugar groups for treatment of diseases associated with heat shock protein pathway. The compounds having the following formulas, wherein variables are as defined herein...
|
|
WO/2019/215633A1 |
The present invention is directed to 5,5-difluoro- and 5-fluoro-5-methyl-C-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more par...
|
|
WO/2019/213579A1 |
Disclosed herein are compounds having antiviral activity, and, in particular, an inhibitory activity on the replication of Respiratory Syncytial Virus (RSV). Druggable target sites, including Px, in the RSV N protein are disclosed, as we...
|
|
WO/2019/199621A1 |
The present invention is directed to bi-functional compounds which find use as pharmaceutical agents in the treatment of disease states and/or conditions which are through.macrophage migration inhibitory factor (MIF) or immunoglubin G (I...
|
|
WO/2019/196262A1 |
The present invention relates to the field of pharmaceutical synthesis, and in particularly relates to a preparation method for a hexahydrofuro-furan-ol derivative, and an intermediate of the derivative and a preparation method therefor....
|
|
WO/2019/199634A1 |
The present invention is directed to bifunctional small molecules which contain a circulating protein binding moiety (CPBM) linked through a linker group to a cellular receptor binding moiety (CRBM) which is a membrane receptor of degrad...
|
|
WO/2019/185026A1 |
Disclosed are a class of glucoside derivatives which act as SGLT1/SGLT2 dual inhibitors, and a use of same in the preparation of drugs acting as SGLT1/SGLT2 dual inhibitors. The derivatives are compounds represented by formula (I), isome...
|
|
WO/2019/188717A1 |
The present invention addresses the problem of providing a compound which is capable of forming a radical polymerization initiator that exhibits excellent heat resistance and solubility. The present invention is a compound represented by...
|
|
WO/2019/171278A1 |
The present invention is directed to heterocycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and / or GPR40 receptors. 5 More particul...
|
|
WO/2019/173772A1 |
The present disclosure is directed to l-(2-hydroxy-4-methylcyclohexyl)-ethanone derivatives having unique and desired flavor and/or fragrance characteristics, as well as the synthesis and application of the derivatives. The compounds of ...
|
|
WO/2019/145726A9 |
Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R5b X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases an...
|
|
WO/2019/172830A1 |
The present disclosure concerns use of compounds of formula I, or salts thereof, as reactive matrices for desorption and laser ablation ionization spectrometry. The disclosure further concerns compounds of formula II, or salts thereof, a...
|
|
WO/2019/166958A1 |
Sotagliflozin may be prepared using schemes and intermediates disclosed herein. Sotagliflozin may be incorporated into pharmaceutical dosage forms for treatment of diabetes.
|
|
WO/2019/166019A1 |
Disclosed in the present invention are pyran fused ring compounds, preparation methods therefor and the use thereof, in particular pyran fused ring compounds which can be used for preparing halichondrin, eribulin or analogues thereof, pr...
|
|
WO/2019/168866A1 |
Substituted cyclohexyl chemical entities of Formula (I): wherein Ra, G, and Rb have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods,...
|
|
WO/2019/159957A1 |
Provided is a polymerizable compound represented by formula (1). In formula (1), one of eight hydrogen atoms is substituted with a (meth)acryloyloxy group, and the remaining seven hydrogen atoms are independently either unsubstituted or ...
|
|
WO/2019/160150A1 |
This novel valerolactone-based compound is represented by formula (I). [In the formula, X represents an allyl group, an aryl group, an ethynyl group, or a butenyl group. Y represents a single bond or a hydroxymethylene group, and Z repre...
|
|
WO/2019/155485A1 |
The present invention relates to the process for the preparation of Pyrylium salts having the formula represented below. Present invention provide a simplified method of producing symmetrical and unsymmetrical pyrylium salts. The inventi...
|
